EKSO Ekso Bionics Holdings Inc

Ekso Bionics to Showcase Its Device Technology in ‘AI for Good’ Webinar on Tuesday, November 19

Ekso Bionics to Showcase Its Device Technology in ‘AI for Good’ Webinar on Tuesday, November 19

SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Katherine Strausser, Principal Controls Engineer at Ekso Bionics, will be participating in an ‘AI for Good’ webinar.

The webinar, entitled “AI-powered Exoskeletons Revolutionizing Rehabilitation and Mobility”, will take place on Tuesday, November 19 at 10:00 a.m. ET. The session will explore the latest exoskeleton technologies and challenges, illustrating how these technologies are not just assisting in overcoming physical limitations but are paving the way for a new era in medical rehabilitation. To register for the webinar, .

Katherine holds a Ph.D. in Mechanical Engineering and a master’s degree from the University of California at Berkeley, and a bachelor’s degree from Carnegie Mellon University. As one of the original inventors of the EksoNR device, Katherine primarily focuses on controls systems for robotics and the interaction of humans with exoskeleton devices.

About Ekso Bionics® 

Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: or follow @EksoBionics on X.

Contact:

David Carey

212-867-1768



EN
18/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ekso Bionics Holdings Inc

 PRESS RELEASE

Ekso Bionics Prices $5.852 million Private Placement

Ekso Bionics Prices $5.852 million Private Placement SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and accredited investors for the purchase and sale of an aggregate of 5,852 shares of the Company’s Series B Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of common stock o...

 PRESS RELEASE

Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor o...

Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s rehabilitation system in the United States. The Bal...

 PRESS RELEASE

Ekso Bionics Announces $3.7 Million Registered Direct Offering of Comm...

Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on October 28, 2025, it entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 769,490 shares of the Company’s common stock at a purchase price of $4.81 per share of common stock in a registered direct offering...

 PRESS RELEASE

Ekso Bionics Reports Third Quarter 2025 Financial Results

Ekso Bionics Reports Third Quarter 2025 Financial Results SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights and Accomplishments Revenue grew 2% year-over-year and rebounded 105% sequentially quarter-over-quarter to $4.2 millionGross margin increased 680 basis points year-over-year and 2,050 basis points sequential...

 PRESS RELEASE

Ekso Bionics Reports Second Quarter 2025 Financial Results

Ekso Bionics Reports Second Quarter 2025 Financial Results SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group (“Bionic P&O”) as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, suppor...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch